Profile data is unavailable for this security.
About the company
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-137.29m
- Incorporated2016
- Employees143.00
- LocationAdicet Bio Inc131 Dartmouth Street, 3Rd FloorBOSTON 02116United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (302) 655-5049
- Websitehttps://www.adicetbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verastem Inc | 10.00m | -89.49m | 115.90m | 73.00 | -- | 4.11 | -- | 11.59 | -3.34 | -3.34 | 0.3726 | 1.49 | 0.0672 | -- | 2.00 | 136,986.30 | -60.16 | -62.70 | -72.65 | -75.18 | -- | -- | -894.91 | -406.17 | -- | -- | 0.5052 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -19.47m | 116.03m | 10.00 | -- | -- | -- | -- | -0.939 | -0.939 | 0.00 | -0.073 | 0.00 | -- | -- | 0.00 | -171.13 | -- | -333.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
| Coherus Biosciences Inc | 308.13m | -29.34m | 117.51m | 246.00 | -- | -- | -- | 0.3814 | -0.4014 | -0.4014 | 2.74 | -0.7301 | 0.5385 | 2.86 | 1.95 | 1,006,974.00 | -5.13 | -21.43 | -11.46 | -29.32 | 41.51 | 79.01 | -9.52 | -36.56 | 1.07 | -4.02 | 1.47 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 117.82m | 25.00 | -- | 3.81 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 119.13m | 93.00 | 8.25 | 1.26 | 6.60 | 211.60 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Regulus Therapeutics Inc | 0.00 | -35.39m | 119.15m | 31.00 | -- | 1.21 | -- | -- | -1.26 | -1.26 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -47.90 | -53.74 | -52.71 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Nuvectis Pharma Inc | 0.00 | -21.10m | 121.24m | 13.00 | -- | 9.73 | -- | -- | -1.29 | -1.29 | 0.00 | 0.6682 | 0.00 | -- | -- | 0.00 | -97.61 | -- | -128.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Assembly Biosciences Inc | 21.48m | -45.61m | 123.29m | 65.00 | -- | 3.55 | -- | 5.74 | -9.32 | -9.32 | 4.28 | 5.47 | 0.2362 | -- | 125.62 | 330,476.90 | -50.15 | -39.69 | -69.22 | -44.03 | -- | -- | -212.33 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Cardiff Oncology Inc | 665.00k | -40.88m | 124.75m | 31.00 | -- | 2.33 | -- | 187.60 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -30.58m | 124.97m | 140.00 | -- | 41.77 | -- | -- | -1.18 | -1.18 | 0.00 | 0.056 | 0.00 | -- | -- | 0.00 | -95.14 | -- | -154.95 | -- | -- | -- | -- | -- | -- | -21.58 | 0.8416 | -- | -- | -- | -11.06 | -- | -- | -- |
| Agenus Inc | 159.63m | -223.67m | 125.98m | 389.00 | -- | -- | -- | 0.7892 | -11.27 | -11.27 | 8.03 | -11.42 | 0.4723 | -- | 154.98 | 410,357.30 | -68.45 | -55.02 | -281.52 | -115.31 | 99.51 | -- | -144.94 | -102.92 | -- | -0.9185 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Adicet Bio Inc | 0.00 | -137.29m | 126.07m | 143.00 | -- | 0.5362 | -- | -- | -2.53 | -2.53 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -50.25 | -37.03 | -53.87 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Puma Biotechnology Inc | 219.14m | 8.72m | 127.52m | 185.00 | 14.21 | 2.60 | 6.28 | 0.5819 | 0.183 | 0.183 | 4.56 | 1.00 | 1.08 | 7.07 | 7.38 | 1,184,557.00 | 4.30 | -12.21 | 7.24 | -20.53 | 73.08 | 78.78 | 3.98 | -11.79 | 1.23 | 1.99 | 0.6474 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Vigil Neuroscience Inc | 0.00 | -83.84m | 129.25m | 64.00 | -- | 1.44 | -- | -- | -2.12 | -2.12 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -59.07 | -- | -63.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| TriSalus Life Sciences Inc | 24.74m | -57.21m | 131.32m | 112.00 | -- | -- | -- | 5.31 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Fractyl Health Inc | 119.00k | -65.88m | 133.72m | 102.00 | -- | 1.89 | -- | 1,123.67 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Adicet Bio Inc's reporting currency: US Dollar USD
41.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 30 Jun 2024 | 8.22m | 9.97% |
| RA Capital Management LPas of 30 Jun 2024 | 7.54m | 9.15% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 4.27m | 5.18% |
| Millennium Management LLCas of 30 Jun 2024 | 3.62m | 4.40% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.09m | 3.75% |
| Aquilo Capital Management LLCas of 30 Jun 2024 | 2.53m | 3.07% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 1.51m | 1.84% |
| Blackstone Alternative Asset Management LPas of 30 Jun 2024 | 1.24m | 1.50% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 1.11m | 1.34% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 1.09m | 1.32% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
